New DNA aptamer stabilises atherosclerosis plaques
The nucleic acid drug, iSN04, could have applications for pathological angiogenesis involved in atherosclerosis, cancer, and retinopathy.
List view / Grid view
The nucleic acid drug, iSN04, could have applications for pathological angiogenesis involved in atherosclerosis, cancer, and retinopathy.
Targeting the epigenetic states of specific retroelements in the human genome could mitigate the biological effects of ageing.
The new study demonstrated that a small molecule inhibitor, BLZ945, could be used as a potential therapeutic to achieve viral clearance.
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
Researchers have obtained images with a previously unseen level of detail, demonstrating how RNA polymerase opens the transcription bubble.
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
In this episode, we explore our understanding of DNA and its implications for health outcomes. Additionally, we discuss the transition from DNA sequencing to actionable insights in medicine, contrasting genetics-driven drug discovery with traditional methods. Finally, we examine the evolving landscape of genetic technology and its potential impact on the…
Epigenetic data assessing the effects of smoking on DNA methylation could serve as biomarkers of exposure effects.
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
New findings about how long genes become less active with age could impact treatments for neurodegeneration, among other conditions.
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
In this Q&A, Aki Ko, CEO and co-founder of Elixirgen Therapeutics, elucidates how their new mRNA technology could potentially restore muscle function in those suffering from Duchenne muscular dystrophy.
Scientists have reported a promising technique, based on somatic cell nuclear transfer, to treat infertility.